CN106074472A - A kind of medicine treating alimentary canal inflammation - Google Patents
A kind of medicine treating alimentary canal inflammation Download PDFInfo
- Publication number
- CN106074472A CN106074472A CN201610396912.4A CN201610396912A CN106074472A CN 106074472 A CN106074472 A CN 106074472A CN 201610396912 A CN201610396912 A CN 201610396912A CN 106074472 A CN106074472 A CN 106074472A
- Authority
- CN
- China
- Prior art keywords
- medicine
- alimentary canal
- canal inflammation
- basic fuchsin
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
Abstract
It is an object of the invention to provide a kind of medicine treating alimentary canal inflammation, this medicine, with basic fuchsin as active component, is equipped with the pharmaceutically acceptable adjuvant of basic fuchsin or complementary composition.Gastral inflammatory lesion can thoroughly be treated by this medicine, has no side effect, and after oral 2 years, Liver and kidney is normal, and draws materials conveniently, and price is honest and clean, and beneficially industrialization produces.
Description
Technical field
The present invention is belonging to field of medicaments, provides a kind of medicine treating alimentary canal inflammation especially, and its active component is
Basic fuchsin, with medically acceptable adjuvant medical starch synthetic drug, can thoroughly cure esophagitis, gastritis, stomach burst
The gastral inflammation such as infections, gastric erosion.
Background technology
The energy source of human body is by pickuping food, and the needs absorbing supply human body energy through enteral digestion remain raw
The continuity of life.So digestion is one of important physiological function of human body.By a series of digestion processes, feeding various battalion
Form point, including carbohydrate, protein, fat, vitamins, inorganic salts and some trace element, be changed into simple
The form being prone to absorb, then by intestinal absorption, become substance in vivo and utilize for body tissue, wherein residual without nutritive value
Slag and unabsorbed part constitute feces and are excreted.In addition digestive system still has certain removing noxious substance or causes a disease
The ability of microorganism, and participate in the immunologic function of body.Digestive system is also secreted multiple hormone and is participated in native system and systemic physiological
The regulation of function.
The completing of digestion process relies on gastral physical action and chemical action and between the two mutually coordinated, this
A little is all to be realized by the neural and regulation of body fluid.But due to the mankind difference of living environment, diet in survival processes
The difference of custom, various chemicalses and the intrusion of food additive, and the factor of each side such as stress and family history, give
Each organ of human body causes infringement in various degree, makes the mankind undertake spirit and the misery of the human body greatly, makes digestive system
Disease the most common.Digestive system includes: the organs such as esophagus, stomach, intestinal, liver, gallbladder, pancreas all belong to digestive system.
No matter which impaired organ can directly or indirectly affect is digested and assimilated and stores.So gastral health is human body
Healthy first important link.
In recent years due to the change of the factors such as human diet structure and living habit, digestive system disease has rising to become
Gesture, owing to esophagitis, gastritis, gastric ulcer, gastric erosion, enteritis etc. are all multi-pathogenesis diseases, is also global frequently-occurring disease, but not
Same country, different areas, its sickness rate differs greatly.According to estimates the total incidence of primary disease can account for the 10 12 of population with
On, male is more than women.
In medical circle, the disease of digestive system not being had good way at present, be mostly symptomatic treatment, excision is main
Method to be effected a radical cure.Less than operation index, based on alleviating pain.Current medication such as antacid, anticholinergic agents, H2 are subject to
Body antagonistic.As protected the medicine of gastric mucosa, sulfur powder aluminum, agent, sweet platinic acid and the application of antibiotic medicine, spirillum is surpassed
Mark, mostly with Norfloxacin in treatment of male, but stomach itself is all caused the biggest injury by all of antibiotic, also has liver, kidney again simultaneously
The biggest damage.Result is the most more harm than good.This disease brings great misery to the mankind and family.So gastral inflammation
Disease, ulcer, erosion are one of a great problems perplexing the mankind.
Summary of the invention
It is an object of the invention to provide a kind of medicine treating alimentary canal inflammation, this medicine becomes with basic fuchsin for activity
Point, with medically acceptable adjuvant medical starch synthetic drug, at treatment esophagitis, gastritis, gastric ulcer, gastric mucosa are rotten
The alimentary canal inflammation effects such as rotten, enteritis (including tuberculous enteritis) are notable, have no side effect, with the livers of latter more than 2 years, stomach just
Often, the patient for gastritis takes pain disappearance in 10 days, and for rotten to the corn patient, first quarter moon eliminates feeling of repletion, and pain disappears.
The present invention specifically provides a kind of medicine treating alimentary canal inflammation, it is characterised in that: described medicine is used for treating
Alimentary canal inflammation, its active component is basic fuchsin.
The medicine for the treatment of alimentary canal inflammation of the present invention, it is characterised in that: this medicine contains basic fuchsin pharmaceutically may be used
The adjuvant accepted or complementary composition, described adjuvant or complementary composition are selected from medical starch, Semen sojae atricolor powder, plumule, Rhizoma Dioscoreae powder, work
One or more of property charcoal.
The medicine for the treatment of alimentary canal inflammation of the present invention, it is characterised in that: this medicine neutral and alkali magenta and basic fuchsin
The weight ratio of pharmaceutically acceptable adjuvant or complementary composition is 25～85:30～75.
The medicine for the treatment of alimentary canal inflammation of the present invention, it is characterised in that: described medicine is oral formulations, unguentum, sheet
Agent, capsule, injection, tincture, powder, electuary, suppository, cream or preparation capable of permeating skin.
Basic fuchsin is the strongest core dyestuff, can make glutinous protein Elastic tissue and fuchsinophile granules stain, nervus centralis
Nuclear staining agent.Bacteriology is used for differentiating tubercule bacillus, prepares Schiff's reagent inspection aldehydes, with bromate titration in analytical chemistry
Oxidation-reduction indicator, is used for contaminating cotton, fiber crops, staple fibre, straw, leather feather, fat etc., is also used for manufacturing color fixed.Alkalescence
Pinkish red be typically by aniline, ortho-aminotoluene, para-totuidine hydrochlorate in the presence of ferrum and zinc chloride with Nitrobenzol melt condensation,
Carrying through acid, neutralize crystallization and make, its chemical structural formula is as follows:
1, chemical structural formula:
2, molecular formula and component:
Formula I: C20H20N3CL=337.84
Formula II: C19H18N3CL=323.82
3, character:
Crystallize for green metal gloss, be dissolved in ethanol and valeric acid, be slightly soluble in water, take on a red color at aqueous solution, insoluble in ether.
4, the change of body fluid pH value after people takes basic fuchsin:
When patient takes basic fuchsin, the trend that the pH value of body fluid (urine) is increased significantly, and make to be infected by bacterial
The acidic physique caused returns to optimal alkalescence body constitution, is conducive to strengthening the immunity of human body, makes the immunity of body
Reach optimum state.After taking medicine, the change of human body urine ph values is shown in Table 1:
After table 1 is taken medicine, human body urine ph values changes
Note: human urine pH value peaks for all 2-3 hour after taking basic fuchsin, and the sustainable 3-4 in peak period is little
Time, and recover normal in 5-6 hour after taking basic fuchsin.
Urine: excrete (table 1) for about 4-6 hour
Just: within about 12-24 hour, excrete (perusal)
Note: 1). the pH value change of urine can be returned the pH value before taking medicine, the most sustainable more than 2h by 5.5-7.5.
2). urine all peaked at 2-3 hour, recovered normal at 5-6 hour.
3). mostly sooner or later service once treatment gastritis, gastric ulcer, the patient of gastric mucosal erosion, such patient body fluid
Alkaline environment can double, the healing of the recovery of the body's immunity that is highly advantageous to, beneficially ulcer surface and reparation.
5, pharmaceutical methods:
The composition proportion of described medicine is weight ratio:
Basic fuchsin: medical starch=55～65:35～45.
6, dose: for basic fuchsin active component 300 600mg/ day, depending on the state of an illness.
7, patient's instructions of taking:
Take 300 600mg basic fuchsins every day, according to the state of an illness can early the most bfore meals once, or the most each the most once.Three
The moon is a course for the treatment of, according to state of an illness changeable dose.
8, therapeutic effect:
1., treatment esophagitis, the alimentary canal inflammation such as gastritis, gastric ulcer, gastric mucosal erosion, enteritis (including tuberculous enteritis)
Effect is notable.
2. after, patient cures, Liver and kidney is the most harmless.
9, the advantage that basic fuchsin cures gastral inflammation:
1., nontoxic: normal for patient's Liver and kidney of 2 years is administered orally.
2., draw materials conveniently, be conducive to promoting and industrialization.
3., price honest and clean, give country and individual reduce the heavy burdens.
4., thorough treatment: the patient after treatment, effect is notable (see embodiment).
5., treatment is convenient: is administered orally, need not be in hospital.
6., medicine retain the most in vivo, and by momentary for body fluid have improve the effect of pH value.
Accompanying drawing explanation
Urine ph values situation over time after Fig. 1 human administration.
Detailed description of the invention
Basic fuchsin used by the present embodiment is purchased from Tianjin Ju Hua Chemical Co., Ltd..
Embodiment 1
Basic fuchsin virulence experiment:
Material: albino guinea-pig totally 24, purchased from Shenyang Pharmaceutical University, conventional raising；
Basic fuchsin, Tianjin Ju Hua Chemical Co., Ltd..
The proportioning packet of laboratory animal: experiment is randomly divided into 4 groups (often group 6, male and female half and half) with Cavia porcellus, is respectively sky
White matched group, basic fuchsin high, medium and low dosage group.
Medication: every Cavia porcellus is administered once set time in the morning every day, high, medium and low three the dosage groups of basic fuchsin
Dosage is respectively 8mg/kg body weight/d, 6mg/kg body weight/d, 4mg/kg body weight/d；Administration time is 21 days, observe every day 3～
4 times, observe Cavia porcellus spirit, appetite, by hair glossiness, physical state, Vigilance and hide the abilities such as seizure.Have no after 21 days
Any change.
Embodiment 2
After taking basic fuchsin, within the different time basic fuchsin by the phenomenon of blood it can be seen that alkalescence product
The red state to dissolve is absorbed into blood, and by entering the process of hemocyte, the antibacterial in phagocyte can be made to have and alkali
Property the chance that combines of magenta, improve again the pH value of body fluid simultaneously.Destroy the weak acid environment of bacterial growth, make antibacterial be killed
Go out.The immune system that body now can be promoted powerful plays one's part to the full.
Hemogram is seen and is looked into:
One, object is seen:
1. physical examination of healthy population makees the normal population object of observation.
2. volunteer of fully recovering in patient makees experimental subject.
Two, instrument:
Binocular biological microscope XSP-12G type
Manufacturer: river light Instrument Factory
Three, reagent:
1. Rui Shi-Ji's nurse Sa Albert'stain Albert liquid (commercially available)
2. phosphate buffer (commercially available)
Four, operational approach:
1. take healthy premenopausal volunteers peripheral blood push jack (normal control blood sheet is standby)
2. take after volunteer is administered orally basic fuchsin the peripheral blood push jack at different time and (accurately take oral alkali at different time
Property magenta peripheral blood push jack is standby).
3. after having taken a blood sample for the last time, together dye with the blood sheet of normal control, treat dry standby.
Five, observe in the object lens (oil mirror) expanding 100X and the ocular microscopes of expansion 12.5X, in kind to expand 1250
Times state under check, the results are shown in Table 2:
Table 2 observed result
Observed result:
1., after taking basic fuchsin, the basic fuchsin entering blood through absorption of human body enters in hemocyte by blood circulation,
About 2-4 hour is retained intracellular.
2. the growth and breeding environment of antibacterial is faintly acid (pH7.0-7.2), and basic fuchsin enters intracellular or antibacterial
In thalline, directly destroy the living environment of antibacterial, make antibacterial to survive, be this sick basic place cured.
Embodiment 3
Case illustrates:
1. patient is to make a definite diagnosis through regular hospital, the patient that long-term medical cannot be cured and repeatedly be recurred.
2. through patient that traditional treatment liver, kidney are impaired, it is impossible to carry out continual cure.
3. before taking medicine, there is obvious symptom.
4. after taking medicine, liver, kidney and other organs are the most normal.
Medicine used by patient: basic fuchsin (inside adds medical starch).
Patient dosage: capsule 600mg/ grain (wherein basic fuchsin: medical starch=55～65:35～45), 1-2 grain/
Day.
Instructions of taking: every day early 1-2 grain bfore meals or sooner or later respectively take 1, fixed according to the state of an illness, specifically refer to table 3,4.
Table 3 patient information table
Table 4 disease ephemeris
Above-described embodiment, only for technology design and the feature of the explanation present invention, its object is to allow person skilled in the art
Scholar will appreciate that present disclosure and implements according to this, can not limit the scope of the invention with this.All according to the present invention
The equivalence that spirit is made changes or modifies, and all should contain within protection scope of the present invention.
Claims (7)
1. the medicine treating alimentary canal inflammation, it is characterised in that: described medicine is used for treating alimentary canal inflammation, and its activity becomes
It is divided into basic fuchsin.
2. according to the medicine treating alimentary canal inflammation described in claim 1, it is characterised in that: this medicine contains basic fuchsin pharmacy
Upper acceptable adjuvant or complementary composition.
3. according to the medicine treating alimentary canal inflammation described in claim 2, it is characterised in that: described basic fuchsin pharmaceutically can connect
The adjuvant being subject to or complementary composition be medical starch, Semen sojae atricolor powder, plumule, Rhizoma Dioscoreae powder, activated carbon one or more.
4. described in claim 1,2 or 3, treat the medicine of alimentary canal inflammation, it is characterised in that: this medicine includes alkalescence product
Red and the pharmaceutically acceptable adjuvant of basic fuchsin or complementary composition, its weight ratio is 25～85:30～75.
5. according to the medicine treating alimentary canal inflammation described in claim 1, it is characterised in that: the consumption of described medicine is alkalescence product
Red active component 300-600mg/ day.
6. according to the medicine treating alimentary canal inflammation described in claim 1, it is characterised in that: described medicine is oral formulations, cream
Agent, tablet, capsule, injection, tincture, powder, electuary, suppository, cream or preparation capable of permeating skin.
7. the application in terms for the treatment of alimentary canal inflammation of the medicine described in a claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610396912.4A CN106074472A (en) | 2016-06-07 | 2016-06-07 | A kind of medicine treating alimentary canal inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610396912.4A CN106074472A (en) | 2016-06-07 | 2016-06-07 | A kind of medicine treating alimentary canal inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074472A true CN106074472A (en) | 2016-11-09 |
Family
ID=57448656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610396912.4A Pending CN106074472A (en) | 2016-06-07 | 2016-06-07 | A kind of medicine treating alimentary canal inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074472A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755308A (en) * | 2012-08-01 | 2012-10-31 | 中国人民解放军第三0二医院 | Application of basic fuchsin to preparation of medicament for treating gastric ulcer |
| CN102755307A (en) * | 2012-08-01 | 2012-10-31 | 中国人民解放军第三0二医院 | Application of basic fuchsin to preparation of medicament for treating canker sore |
| CN103933367A (en) * | 2014-05-05 | 2014-07-23 | 青岛市市立医院 | Traditional Chinese medicine formula of navel patch for treating atrophic gastritis and preparation method of traditional Chinese medicine formula |
-
2016
- 2016-06-07 CN CN201610396912.4A patent/CN106074472A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755308A (en) * | 2012-08-01 | 2012-10-31 | 中国人民解放军第三0二医院 | Application of basic fuchsin to preparation of medicament for treating gastric ulcer |
| CN102755307A (en) * | 2012-08-01 | 2012-10-31 | 中国人民解放军第三0二医院 | Application of basic fuchsin to preparation of medicament for treating canker sore |
| CN103933367A (en) * | 2014-05-05 | 2014-07-23 | 青岛市市立医院 | Traditional Chinese medicine formula of navel patch for treating atrophic gastritis and preparation method of traditional Chinese medicine formula |
Non-Patent Citations (1)
| Title |
|---|
| 冷长春: "鬼子红治疗颈淋巴结结核", 《四川中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geissler et al. | Medicinal plants used by Luo mothers and children in Bondo district, Kenya | |
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| Boden | Black's veterinary dictionary | |
| CN103719609B (en) | Feed for lactating sows and preparation method thereof | |
| CN104351563A (en) | Functional feed used for preventing pig malignant edema and preparation method of functional feed | |
| CN104256167A (en) | Functional feed for preventing and treating sheep stomatitis and preparation method thereof | |
| CN101314004B (en) | Medicament for treating gynaecologic urinary system infection contamination and preparation method thereof | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN104351571A (en) | Feed for preventing fish infectious hematopoietic necrosis and preparation method thereof | |
| CN106974952A (en) | Application of the fresh ginseng activity extract in treatment oral cavity and digestive tract ulcer medicine is prepared | |
| CN104256165B (en) | For preventing and treating functional feed of chronic type swine fever epidemic disease and preparation method thereof | |
| CN105943666B (en) | Composition for nursing sensitive skin of infant and preparation method thereof | |
| CN110354224A (en) | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa, antipruritic, taste of dispelling | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN101244164A (en) | Medicament for preventing and treating hydropsy of pigling | |
| CN106109564A (en) | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof | |
| CN102188494A (en) | Medicament for treating high fever of pigs with pure Chinese medicine | |
| CN105104887A (en) | Cattle compound feed and preparation method thereof | |
| CN106074472A (en) | A kind of medicine treating alimentary canal inflammation | |
| CN101138581B (en) | Traditional chinese medicine preparation for treating urinary system infection contamination and method of preparing the same | |
| CN105326954B (en) | A kind of Chinese medicine composition and preparation method thereof for treating blear-eye | |
| CN104042879B (en) | Traditional Chinese medicine granules for reversing precancerous lesions of chronic atrophic gastritis and preparation method thereof | |
| CN101953871A (en) | Antibacterial medicament for animals and preparation method and application thereof | |
| CN101987117A (en) | Traditional Chinese medicine composition for treating bacterial diseases in poultry and livestock and preparation method thereof | |
| CN109260185A (en) | A kind of drug for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |